A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 08 May 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms EARLiMS
- Sponsors Novare Pharmaceuticals; Novartis
- 03 May 2017 Status changed from recruiting to completed.
- 22 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.
- 22 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2016.